Patient - PACT

New Clinical Trial and Research

Trial title	An Open Label Study of the Efficacy, Safety and Tolerablity of Np-120 on Idiopathic Pulmonary Fibrosis and its Associated Cough
Trial synopsis	Idiopathic Pulmonary Fibrosis is a disease that causes scarring in the lungs that leads to shortness of breath and a persistent cough. The purpose of this research project (study) is to test the effectiveness of Ifenprodil in reducing cough and improving quality of life, and to collect safety information about Ifenprodil, in people with persistent cough due to IPF. Ifenprodil was originally developed as a vasodilator to open up blood vessels to help blood flow. It has an established safety record and has been used in France and Japan for almost 50 years. The ability of Ifenprodil to reduce pulmonary fibrosis and cough has been demonstrated in laboratory research. This study will be the first time Ifenprodil is being used in people with IPF. Medications, drugs and devices have to be approved for use by the Therapeutic Good Administration (TGA) in Australia. Ifenprodil (NP-120) is an experimental treatment. This means that it is not an approved treatment for idiopathic pulmonary fibrosis (IPF) in Australia or any other country.
Investigational medicinal product	Ifenprodil (NP-120)
Disease target	Idiopathic Pulmonary Fibrosis with cough
Sponsor	Algernon Pharmaceuticals, Inc
Duration	Participant duration is 13 weeks
Trial Status	Recruiting
Lead site(s) in Australia	Cairns Hospital (public) / Vale Medical Practice (private)
Lead site(s) in New Zealand	Waikato Hospital
Additional sites	Concord Repatriation General Hospital NSW, Westmead Hospital NSW, University of Otago
Contact	pactcoordinator@cre-pf.org.au